221 related articles for article (PubMed ID: 15117932)
21. [New therapeutic strategies with teicoplanin].
Carbone E; Nacinovich F; Stamboulian D
Medicina (B Aires); 2002; 62 Suppl 2():25-9. PubMed ID: 12481485
[TBL] [Abstract][Full Text] [Related]
22. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections.
Finney MS; Crank CW; Segreti J
Curr Med Res Opin; 2005 Dec; 21(12):1923-6. PubMed ID: 16368041
[TBL] [Abstract][Full Text] [Related]
23. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
[TBL] [Abstract][Full Text] [Related]
24. Dalbavancin: a novel lipoglycopeptide antibacterial.
Pope SD; Roecker AM
Pharmacotherapy; 2006 Jul; 26(7):908-18. PubMed ID: 16803423
[TBL] [Abstract][Full Text] [Related]
25. Early experience with linezolid for infections in orthopaedics.
Harwood PJ; Talbot C; Dimoutsos M; Sunderland G; Shaw D; Wilcox MH; Giannoudis PV
Injury; 2006 Sep; 37(9):818-26. PubMed ID: 16620816
[TBL] [Abstract][Full Text] [Related]
26. Optimizing therapy for vancomycin-resistant enterococci (VRE).
Linden PK
Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
[TBL] [Abstract][Full Text] [Related]
27. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
Cornaglia G; Rossolini GM
Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
[TBL] [Abstract][Full Text] [Related]
28. Use of linezolid in children: an overview of recent advances.
Velissariou IM
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
[TBL] [Abstract][Full Text] [Related]
29. Orthopaedic infections: organisms and antibiotic sensitivity.
Yusof MI; Yusof AH
Med J Malaysia; 2004 Dec; 59(5):574-7. PubMed ID: 15889557
[TBL] [Abstract][Full Text] [Related]
30. Experience with linezolid therapy in children with osteoarticular infections.
Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC
Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with daptomycin: bacteraemia and endocarditis.
Levine DP
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series.
Rao N; Hamilton CW
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):173-9. PubMed ID: 17574788
[TBL] [Abstract][Full Text] [Related]
33. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
Lundstrom TS; Sobel JD
Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
[TBL] [Abstract][Full Text] [Related]
34. Current and emerging serious Gram-positive infections.
Menichetti F
Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
[TBL] [Abstract][Full Text] [Related]
35. New drugs for Gram-positive uropathogens.
Wagenlehner FM; Naber KG
Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S39-43. PubMed ID: 15364305
[TBL] [Abstract][Full Text] [Related]
36. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
Jones RN
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115
[TBL] [Abstract][Full Text] [Related]
37. Fighting infections due to multidrug-resistant Gram-positive pathogens.
Cornaglia G
Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
[TBL] [Abstract][Full Text] [Related]
38. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients].
Pensotti C; Nacinovich F; Vidiella G; Carbone E; Marin M; Di Stéfano C; Stamboulian D
Medicina (B Aires); 2002; 62 Suppl 2():40-7. PubMed ID: 12481488
[TBL] [Abstract][Full Text] [Related]
39. Linezolid for the treatment of adults with bone and joint infections.
Falagas ME; Siempos II; Papagelopoulos PJ; Vardakas KZ
Int J Antimicrob Agents; 2007 Mar; 29(3):233-9. PubMed ID: 17204407
[TBL] [Abstract][Full Text] [Related]
40. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
Mory F; Fougnot S; Rabaud C; Schuhmacher H; Lozniewski A
J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
